Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer

被引：4
|
作者：
Franco, Fernando [1 ]
Provencio, Mariano [1 ]
机构：
[1] Puerta Hierro Hosp, Med Oncol Dept, Manuel de Falla St 1, Madrid 28222, Spain
来源：
JOURNAL OF THORACIC DISEASE | 2019年 / 11卷 / 10期
关键词：
OPEN-LABEL; PEMBROLIZUMAB; CHEMOTHERAPY; DOCETAXEL;
D O I：
10.21037/jtd.2019.09.68
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：4092 / 4095
页数：4
相关论文
共 50 条
  • [1] Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer
    Laura Gutierrez-Sainz
    Patricia Cruz-Castellanos
    Oliver Higuera
    Javier de Castro-Carpeño
    [J]. Current Treatment Options in Oncology, 2021, 22
  • [2] Neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
    Broderick, Stephen R.
    Bott, Matthew J.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 158 (05): : 1471 - 1474
  • [3] Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer
    Gutierrez-Sainz, Laura
    Cruz-Castellanos, Patricia
    Higuera, Oliver
    De Castro-Carpeno, Javier
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (10)
  • [4] EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer
    Kowalski, D. M.
    Krzakowski, M.
    Jaskiewicz, P.
    Janowicz-Zebrowska, A.
    Glogowski, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Fujino, Toshio
    Suda, Kenichi
    Mitsudomi, Tetsuya
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (03) : 229 - 249
  • [6] Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer
    Nguewa, Paul A.
    Calvo, Alfonso
    Pullamsetti, Soni Savai
    Banat, Gamal Andre
    Grimminger, Friedrich
    Savai, Rajkumar
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (01) : 61 - 74
  • [7] The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
    Kowalczyk, Anna
    Szutowicz-Zielinska, Ewa
    Dziadziuszko, Rafal
    Jassem, Jacek
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (04): : 217 - 224
  • [8] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
    Perol, M.
    Arpin, D.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
  • [9] Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
    Riano, Ivy
    Abuali, Inas
    Sharma, Aditya
    Durant, Jewelia
    Dragnev, Konstantin H. H.
    [J]. PHARMACEUTICALS, 2023, 16 (02)
  • [10] Neoadjuvant Erlotinib Treatment in Patients with Resectable Non-Small Cell Lung Carcinoma
    Van Gool, Matthijs
    Kiomp, Houke
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S644 - S645
12345